稳心颗粒对心房颤动患者射频消融术后早期复发的影响
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2016年第5期
- 页码:
- 546-548
- 栏目:
- 临床研究
- 出版日期:
- 2016-04-25
文章信息/Info
- Title:
- Effect of wenxin granule on early recurrence after radiofrequency ablation in patients with atrial fibrillation
- Author(s):
- KUANG Rong-ren1; XU Yan1; HONG Lei1; LIANG Hua-sheng2; FANG Sheng-xian1
- (1.Department of Cardiology, Longgang Central Hospital, Shenzhen 518116, Guangdong, China；
2.Department of Cardiology, Guangdong Provincial People’s Hospital, Guangzhou 510080, Guangdong, China)
- 分类号:
- R541.1
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察稳心颗粒对心房颤动患者射频消融术后早期复发的影响。 方法 入选拟行房颤射频消融术的住院患者，其中试药组 35例（稳心颗粒组）和对照组 36例。患者射频消融术后常规给予胺碘酮和华法林，试药组加用稳心颗粒。观察两者入院时及术后3个月血清氨基末端B型钠尿肽原（NT-proBNP）水平、入院时及术后3个月左房内径大小及早期复发情况。结果 试药组早期复发率为9%，对照组早期复发率为31%，两组比较差别有显著意义（P<0.05）；术后3个月两组NT-proBNP水平及左房内径呈下降趋势，且试药组明显低于对照组(P<0.05)。结论 稳心颗粒能够减少房颤射频术后早期复发，降低NT-proBNP水平及缩小左房内径。
- Abstract:
- AIM To discuss the effect of wenxin granule on early recurrence after radiofrequency ablation (RFCA) in patients with atrial fibrillation (AF). METHODSPersistent AF patients were randomized into wenxin granule group (n=35) and control group (n=36). The rate of AF early recurrence, NT-proBNP and left atrial diameter were observed before and 3 months after RFCA. RESULTSThe rate of AF early recurrence in wenxin granule group was significantly lower than in control group (8.6% vs. 30.6%; P<0.05). NT-proBNP and left atrial diameter in wenxin granule group were significantly lower than those in the control group 3 months after RFCA (P<0.05). CONCLUSIONWenxin granule can significantly lower the rate of AF early recurrence after RFCA and reduce NT-proBNP and left atrial diameter in patients with AF.
参考文献/References
[1]Aliot E,Breithardt G,Brugada J,et al.An international survey of physician and patient understanding,perception,and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality[J].Europace,2010,12(5):626-633
[2]Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J].Europace,2010,12(10):1360-1420.
[3]Hu D,Sun Y.Epidemiology,risk factors for stroke,and management of atrial fibrillation in China[J].J Am Coll Cardiol,2008,52(10): 865-868.
[4]January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21):e1-e76.
[5]Bertaglia E,Stabile G,Senatore G,et al.Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation[J].Pacing Clin Electrophysiol,2005,28(5):366-371.
[6]Verma A,Jiang CY,Betts TR,et al.Approaches to catheter ablation for persistent atrial fibrillation[J].N Engl J Med,2015,372(19):1812-1822.
[7]Wang XH,Liu X,Sun YM,et al.Pulmonary vein isolation combined with superior vena cava isolation for atrial fibrillation ablation:a prospective randomized study[J].Europace,2008,10(5):600-605.
[8]Patton KK,Ellinor PT,Heckbert SR,et al.N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation:the Cardiovascular Health Study[J].Circulation,2009,120(18):1768-1774.
[9]Schnabel RB,Sullivan LM,Levy D,et al.Development of a risk score for atrial fibrillation(Framingham Heart Study):a community-based cohort study[J].Lancet,2009,373(9665):739-745.
[10]Burashnikov A,Petroski A,Hu D,et al.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation[J].Heart Rhythm,2012,9(1):125-131.
备注/Memo
- 备注/Memo:
- 收稿日期：2015-12-31.
作者简介：匡荣仁，主治医师，硕士 Email： 53922810@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed850
- 评论/Comments
